Attila Szederjesi

Attila Szederjesi

Auto-generated profile, based on publicly available information

Attila Szederjesi

Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Journal of Immunotherapy
Verified
Journal Article
Closed access
KKKrisztián Kállay
Krisztián Kállay
CKCsaba Kassa
Csaba Kassa
MRMarienn Réti
Marienn Réti
ÉKÉva Karászi
Éva Karászi
JSJános Sinkó
János Sinkó
GKGergely Kriván
Gergely Kriván
Viral reactivation is a frequent complication of allogeneic hematopoietic stem cell transplantation especially in children. For refractory cases, rapid virus-specific T-cell therapy would be ideally implemented within a few days. Over the course of a year in our pediatric cohort of 43 allogeneic transplantation, 9 patients fulfilled criteria for virus-specific T-cell therapy. Viral infections were due to cytomegalovirus (CMV) in 3, Epstein-Barr virus (EBV) in 2, and adenovirus (AdV) in 1 case, whereas >1 virus was detected in 3 cases. Viral diseases necessitating a T-cell therapy were CMV pneumonitis and colitis, AdV enteritis and cystitis, and EBV-induced posttransplantation lymphoproliferative disease. Cells were produced by the CliniMACS Prodigy CCS (IFN-gamma) System within 24 hours after mononuclear leukapheresis. Eight patients became completely asymptomatic, whereas 7 also cleared the virus. Six patients are alive without viral illness or sequelae demonstrating viral DNA clearance in peripheral blood with a median follow-up of 535 (350–786) days. One patient with CMV pneumonitis died of respiratory insufficiency. In 2 cases the viral illness improved or cleared, however, the patients died of invasive aspergillosis. No cases of graft-versus-host disease, rejection, organ toxicity, or recurrent infection were noticed. Virus-specific T-cell therapy implemented by the CliniMACS Prodigy CCS (IFN-gamma) System is an automated, fast, safe, and probably effective way to control resistant viral diseases after pediatric hematopoietic stem cell transplantation.

3 November 2022 in Blood
Verified
Journal Article
Open access
PDF file
BSBarbara Simon
Barbara Simon
ACAndrea Ceglédi
Andrea Ceglédi
JDJános Dolgos
János Dolgos
PFPéter Farkas
Péter Farkas
MGManila Gaddh
Manila Gaddh
Imre BodóImre Bodó
Imre Bodó
Acquired hemophilia A (AHA) is a rare severe autoimmune bleeding disorder with significant morbidity and mortality. Although critical for disease control, there is no consensus for the best immunosuppressive regimen. Most authors use steroids first line, followed by other agents for steroid failures. Upfront combined regimens offer the advantage of reduced steroid exposure and toxicity as well as increased efficacy. We retrospectively analyzed data from 32 patients with AHA treated on an identical such institutional protocol: cyclophosphamide 1000 mg on days 1 and 22, dexamethasone 40 mg on days 1, 8, 15, and 22, and rituximab 100 mg on days 1, 8, 15, and 22 (the regimen was termed CyDRi). All patients received at least 1 cycle of CyDRi. If necessary, CyDRi was repeated until remission, no sooner than day 43 of the previous cycle. Bleeding control was rapidly achieved. The median time for bleeding control was 15.5 days (range, 0-429 days; interquartile range, 2.5-29.5 days). Thirty-one (96.8%) of 32 patients achieved durable complete remission (CR); 29 (90.6%) of 32 patients were alive at last follow-up, all of them in CR. The median time to reach first CR was 77 days (range, 19-939 days; interquartile range, 31-115 days). Toxicity and side effects were acceptable and milder than those of commonly used, prolonged steroid therapies. In conclusion, the CyDRi regimen produced markedly higher CR rates and overall survival than currently used sequential regimens. Taken together, CyDRi proved to be an attractive option for the immunosuppression of elderly patients with AHA.

24 October 2017 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
ABA. M. H. P. van Den Besselaar
A. M. H. P. van Den Besselaar
VCV. Chantarangkul
V. Chantarangkul
FAF. Angeloni
F. Angeloni
NBN. B. Binder
N. B. Binder
MBM. Byrne
M. Byrne
ATArmando Tripodi
Armando Tripodi

5 January 2018 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
NGNóra Garam
Nóra Garam
ÉMÉva Maláti
Éva Maláti
GSGyörgy Sinkovits
György Sinkovits
TGTímea Gombos
Tímea Gombos
ASAttila Szederjesi
Attila Szederjesi
ZPZoltán Prohászka
Zoltán Prohászka
Distant metastasis is a major cause of colorectal cancer–related death, but the mechanism of tumour progression is not fully understood. There is growing evidence of an interaction between tumour cells and platelets which may influence tumour progression and metastasis formation. Quality and quantity of von Willebrand factor may regulate the interaction between tumour cells and platelets. Our aim was to measure the platelet count, von Willebrand factor antigen (VWF:Ag) levels and ADAMTS13 activity in a large (n = 232) cohort of colorectal cancer patients and to examine their relationships with the stage of the disease and 5-year survival without thrombotic complications using multivariable models. Significantly higher platelet counts (p = 0.005), VWF:Ag levels (p = 0.008) and decreased ADAMTS13 activity (p = 0.006) were observed in patients with metastatic disease. Results of the Kaplan–Meier analysis showed that lower platelet counts (p < 0.0001), lower VWF:Ag (p = 0.0008) levels and higher ADAMTS13 activity (p < 0.0001) were associated with better event-free survival. Finally, to investigate the association between overall event-free survival and the three study variables, multivariate Cox proportional hazard models were generated. All models were adjusted for age, gender and disease stage. Platelet count, ADAMTS13 activity or VWF:Ag level were incorporated and all of these variables turned out to be age-, gender- and stage-independent predictors of mortality (all hazard ratio >1.7, p < 0.05). In summary, this is the first observational study reporting association between higher mortality or thrombotic complications and increased platelet count, increased VWF:Ag levels and decreased ADAMTS13 activity in colorectal cancer.

13 June 2018 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
ASA. Szederjesi
A. Szederjesi
LBL. Baronciani
L. Baronciani
UBU. Budde
U. Budde
GCG. Castaman
G. Castaman
ALA. S. Lawrie
A. S. Lawrie
Imre BodóImre Bodó
Imre Bodó

30 October 2019 in Vox Sanguinis
Verified
Journal Article
Closed access
PDF file
STSzabolcs Tasnády
Szabolcs Tasnády
ÉKÉva Karászi
Éva Karászi
ASAttila Szederjesi
Attila Szederjesi
GBGyörgy Bihari
György Bihari
ZJZsófia Juhász
Zsófia Juhász
TMTamás Masszi
Tamás Masszi